Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05897372
Other study ID # PRIMETIME - WP3
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date June 1, 2023
Est. completion date June 1, 2025

Study information

Verified date May 2023
Source Herlev Hospital
Contact Iain Bressendorff, MD PhD
Phone +4524277139
Email iain@bressendorff.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this trial is to investigate the feasibility and safety of implementing a protocol-based treatment aggressively targeting albuminuria in subjects with biopsy-proven diabetic nephropathy and severely elevated albuminuria. If this approach is feasible, the results of the trial will inform the design of a large-scale randomized clinical trial to evaluate the effect of this treatment on hard kidney endpoints (initiation of dialysis, kidney transplantation, and death from kidney failure) in subjects with biopsy-proven diabetic nephropathy and severely elevated albuminuria.


Description:

Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease (ESKD) worldwide and declining kidney function is associated with a graded increase in the risk of death or hospitalization. Thus, prevention of kidney disease progression is of vital importance to prevent excess morbidity and mortality among people with DKD. Increasing levels of albuminuria in patients with DKD are associated with a graded increase in the risk of developing ESKD and among patients with nephrotic-range albuminuria (i.e. > 2.000 mg/day) progressive decline in kidney function is particularly rapid. The currently available drugs which have demonstrated delayed progression to ESKD in DKD (captopril, losartan and irbesartan, canagliflozin, dapagliflozin, empagliflozin, and finerenone) all reduce albuminuria independently of blood pressure reductions, but it has long been debated whether reductions in albuminuria by itself reflects a reduction in the risk of ESKD or whether this is simply a by-product of treatment. Whether interventions targeting reductions in albuminuria reduce the incidence of ESKD has not been formally tested in a randomized controlled trial of hard kidney endpoints (e.g. initiation of dialysis, kidney transplantation or death from kidney disease). We wish to conduct a randomized controlled trial in which we will test whether an aggressive treatment strategy of lowering albuminuria reduces the incidence of hard kidney endpoints compared to standard-of-care among patients with nephrotic-range albuminuria and very high risk of progression to ESKD. However, prior to conducting such a trial it is necessary first to test whether it is even possible to sufficiently lower albuminuria by these means. Therefore, we wish to first conduct a pilot trial to investigate the feasibility of such an approach. Participants will be randomized 1:1 to standard-of-care or an albuminuria-reduction protocol. In the albuminuria-reduction protocol, subjects will be treated with various drugs that have all been shown to reduce albuminuria in DKD (although not all have been shown to reduce hard kidney outcomes). At each monthly study visit, drugs will be added or withdrawn in an attempt to maximally reduce albuminuria. Drugs that reduce albuminuria by <10% since the last study visit will be discontinued. Drugs that successfully reduce albuminuria by >10% will be continued and further drugs will be added. After 9 months subjects will discontinue protocol drugs and resume their previous medical care.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date June 1, 2025
Est. primary completion date June 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years - Diagnosis of diabetes mellitus type 2 (American Diabetes Association / European Association for the Study of Diabetes (ADA/EASD) definition)10 - Biopsy-proven diabetic nephropathy - UACR = 2,000 mg/g or - UACR = 1,500 mg/g if treated with sodium-glucose cotransporter 2 inhibitor (SGLT2i) - Estimated glomerular filtration rate (eGFR) = 30 mL/min/1.73 m2 - Negative pregnancy test and use of highly effective and safe contraception - Able to give informed consent. Exclusion Criteria: - Kidney transplant recipient - Findings on kidney biopsy suggestive of other or concomitant glomerulonephritis (findings associated with hypertensive nephropathy are not exclusion criteria). - Plasma potassium at baseline > 5.2 mmol/L. - Active malignancy (basal or squamous cell skin carcinoma, localised prostate cancer, and cancer with no signs of reoccurrence after 5 years are exempt from this). - Systolic heart failure with NYHA class III-IV. - Liver failure classified as Child-Pugh C. - Primary hyperaldosteronism. - Previous cerebral or retinal haemorrhage. - Biliary obstructive disorders. - Acute myocardial infarction within the last three months. - Severe cardiac arrhythmias. - Clinically active gout. - Plasma sodium at baseline < 135 mmol/L. - Other diseases or conditions, which, in the opinion of the site investigator, would prevent participation in or completion of the trial. - Treatment with potent CYP3A4 inhibitors. - Participation in other interventional trials. - Allergy towards one of more of the drugs to be used during the trial

Study Design


Intervention

Drug:
ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib
Standard of care for diabetic kidney disease.

Locations

Country Name City State
Denmark Department of Nephrology, Herlev and Gentofte Hospital Herlev

Sponsors (1)

Lead Sponsor Collaborator
Iain Bressendorff

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary urine albumin/creatinin-ratio (UACR) reduction to less than 50% of baseline number of subjects achieving this endpoint after 9 months of treatment
Secondary UACR reduction to less than 70% of baseline number of subjects achieving this endpoint after 9 months of treatment
Secondary UACR less than 300 number of subjects achieving this endpoint after 9 months of treatment
Secondary difference in UACR between-groups difference in UACR after 9 months of treatment
Secondary difference in UACR between-groups difference in UACR after 10 months of treatment (1 month off study drugs)
Secondary difference in eGFR between-groups difference in eGFR after 9 months of treatment
Secondary difference in eGFR between-groups difference in eGFR after 10 months of treatment (1 month off study drugs)
Secondary difference in blood pressure between-groups difference in blood pressure after 9 months of treatment
Secondary difference in blood pressure between-groups difference in blood pressure after 10 months of treatment (1 month off study drugs)
Secondary incidence of plasma potassium >5.5 mmol/L number of subjects achieving this endpoint after 9 months of treatment
Secondary incidence of plasma potassium >6.0 mmol/L number of subjects achieving this endpoint after 9 months of treatment
Secondary incidence of symptomatic hypotension number of subjects achieving this endpoint after 9 months of treatment
See also
  Status Clinical Trial Phase
Recruiting NCT06006689 - Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis) Phase 2
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT05086549 - An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT02276196 - Effect of LIXIsenatide on the Renal System Phase 4
Not yet recruiting NCT06120569 - Evaluate the Role of Soleus Muscle Exercise in Glycaemic Control in Diabetic Kidney Disease Patients N/A
Completed NCT02545049 - Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease Phase 3
Active, not recruiting NCT02237352 - Mechanisms of Diabetic Nephropathy in Ecuador
Active, not recruiting NCT06176599 - Clinical Study on the Treatment of Diabetic Kidney Disease With Shenxiao Yuning Decoction With Syndrome of Qi and Yin Deficiency and Blood Stasis N/A
Recruiting NCT03716401 - Prognostic Imaging Biomarkers for Diabetic Kidney Disease
Terminated NCT03840343 - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease Phase 1
Completed NCT01377688 - Personalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes N/A
Active, not recruiting NCT05514548 - Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease Phase 2
Recruiting NCT05507892 - Renal Mechanism of SGLT2 Inhibition Phase 2
Not yet recruiting NCT05514184 - Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease N/A
Not yet recruiting NCT06049550 - The Influence of the Thickening of Bowman's Capsule on the Clinical Prognosis of Patients With Diabetic Kidney Disease
Active, not recruiting NCT04589351 - Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe Phase 3
Active, not recruiting NCT04531163 - Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy Phase 2/Phase 3
Active, not recruiting NCT03620773 - Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes Phase 1/Phase 2
Suspended NCT01878045 - Mechanisms of Diabetic Kidney Disease in American Indians